LA JOLLA, Calif.--(BUSINESS WIRE)--Jun 1, 2023--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference.
Management will provide an overview of the Company’s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences.
Conference: | LD Micro Invitational Conference | |
Location: | Luxe Hotel, Los Angeles | |
Date: | Wednesday, June 7 | |
Time: | 11:30 am Pacific Time | 2:30 pm Eastern Time | |
The presentation at the LD Micro conference will be live-streamed on the event website at https://ldinv13.sequireevents.com/. | ||
Conference: | Jefferies Global Healthcare Conference | |
Location: | Marriott Marquis, New York City | |
Date: | Friday, June 9 | |
Time: | 7:30 am Pacific Time | 10:30 am Eastern Time | |
Webcast access for the Jefferies conference will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of the Jefferies conference will be available for 90 days. |
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in a Phase 1 first-in-human clinical study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase 1b clinical study of patients with lupus/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. for the development and commercialization of itolizumab under an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports,which may be accessed for free by visiting the Securities and Exchange Commission’s website atwww.sec.govand onEquillium’swebsite under the heading “Investors.”Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230601005179/en/
CONTACT: Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com
KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RESEARCH INFECTIOUS DISEASES CLINICAL TRIALS STEM CELLS BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE ONCOLOGY
SOURCE: Equillium, Inc.
Copyright Business Wire 2023.
PUB: 06/01/2023 08:00 AM/DISC: 06/01/2023 08:01 AM
http://www.businesswire.com/news/home/20230601005179/en